Metabolic Pathways: Glycolysis, PPP, UDP-Glucose, and Glycogen Storage

Metabolic Fates of Glucose: Glycolysis, PPP, UDP-Glucose, and Glycogen

• Overview of the pathway context:
  • Glucose can be phosphorylated and then fed into multiple fates depending on tissue, hormonal state (fed vs fasted), and energetic demand.
  • The transcript discusses several related pathways: hexose monophosphate shunt (pentose phosphate pathway, PPP), glycolysis, glycogen synthesis/breakdown, and detox/conjugation via UDP-glucuronate. It also emphasizes the role of NADPH in biosynthesis and antioxidant defense, and the hepatic-specific ability to release glucose to blood via glucose-6-phosphatase.

Glucose phosphorylation: entry points and tissue differences

• Key initial step: phosphorylation of glucose to glucose-6-phosphate (G6P) to trap it in cells.
  • In liver and some other tissues, glucokinase (a liver isoform of hexokinase) catalyzes this step and is insulin-responsive.
  • In most other tissues (e.g., muscle), hexokinase catalyzes the step, but is subject to feedback inhibition by G6P.
• Reactions:
  • $\text{Glucose} + \text{ATP} \rightarrow \text{Glucose-6-phosphate} + \text{ADP}$
• The downstream fate of G6P depends on tissue and energy state:
  • In liver, G6P can be dephosphorylated back to glucose for release into blood via glucose-6-phosphatase (G6Pase).
  • In muscle, G6P generally proceeds to glycolysis for energy and cannot be released as free glucose because muscle lacks G6Pase.
• Important note: glucose-6-phosphatase is present mainly in liver and kidney (not in muscle); this underpins the liver’s role in maintaining blood glucose during fasting.
• Mechanistic context from the transcript:
  • The enzyme glucose-6-phosphatase is highlighted as critical for glucose formation when carbohydrate access is limited.
  • A deficiency in this pathway leads to impaired glucose production in fasting, with clinical symptoms (e.g., glycogen storage disease type I).

The Hexose Monophosphate Shunt / Pentose Phosphate Pathway (PPP)

• Also called the hexose monophosphate (HMP) shunt; PPP is repeatedly referenced in the transcript.
• Primary purposes of PPP:
  • Generate NADPH for reductive biosynthesis and antioxidant defense (e.g., maintaining reduced glutathione).
  • Provide ribose-5-phosphate for nucleotide and nucleic acid synthesis.
• Oxidative phase (generates NADPH):
  • $\text{Glucose-6-phosphate} + \mathrm{NADP^+} \rightarrow 6\text{-phosphoglucono-}\delta\text{-lactone} + \mathrm{NADPH}$
  • $6\text{-phosphoglucono-}\delta\text{-lactone} + \mathrm{H_2O} \rightarrow 6\text{-phosphogluconate}$
  • $6\text{-phosphogluconate} + \mathrm{NADP^+} \rightarrow \text{Ribulose-5-phosphate} + \mathrm{CO_2} + \mathrm{NADPH}$
• Non-oxidative phase (recycling and sugar interconversion): ribose-5-phosphate can be converted to glycolytic intermediates (fructose-6-phosphate, glyceraldehyde-3-phosphate) as needed.
• Significance in physiology:
  • NADPH from PPP supports fatty acid and steroid synthesis; helps regenerate reduced glutathione (antioxidant defense) and sustains reductive biosynthesis (e.g., steroids).
  • The transcript emphasizes NADPH as a crucial molecule for antioxidant production and lipid/steroid metabolism.

NADPH, antioxidant defense, and steroidogenesis

• NADPH is a central reducing equivalent produced by PPP.
• Roles mentioned in the transcript:
  • Supports antioxidant defenses (e.g., synthesis/recycling of glutathione).
  • Provides reducing power for lipid and steroid synthesis in tissues with high demand (adrenal glands, adipose tissue).
• Broader context:
  • NADPH is used by various enzymes (e.g., fatty acid synthase, cholesterol/steroid biosynthetic enzymes) and by glutathione reductase to maintain the cellular redox state.
• Takeaway: a high flux through PPP (and thus NADPH production) often accompanies tissues with anabolic and detoxification needs (lipogenesis, steroid synthesis, detoxification).

UDP-glucose, glucuronidation, and detoxification

• UDP-glucose sits at the hub of carbohydrate storage and detox pathways.
• Formation of UDP-glucose:
  • \text{Glucose-1-phosphate} + \text{UTP} \rightarrow \text{UDP-glucose} + \text{PP_i}
• What happens to UDP-glucose?
  • It acts as a donor of glucose units for glycogen synthesis (see Glycogen section).
  • It is oxidized to UDP-glucuronate by UDP-glucose dehydrogenase:
  • $\text{UDP-glucose} + 2\,\mathrm{NAD^+} + \mathrm{H_2O} \rightarrow \text{UDP-glucuronate} + 2\,\mathrm{NADH} + 2\,\mathrm{H^+}$
• UDP-glucuronate and glucuronidation:
  • UDP-glucuronate is a substrate for UDP-glucuronosyltransferases (UGTs) that conjugate glucuronate to various substrates (bilirubin, drugs, xenobiotics), increasing water solubility for excretion.
  • Overall reaction (illustrative):
  • $\text{Substrate} + \text{UDP-glucuronate} \rightarrow \text{Substrate-Glucuronide} + \text{UDP}$
• Clinical/physiological relevance highlighted in the transcript:
  • Detoxification pathway conjugates hydrophobic substances, making them water-soluble for excretion.
  • Excess accumulation of unconjugated toxins or bilirubin can lead to yellow pigmentation (jaundice) if glucuronidation is impaired.

Glycogen: storage form of glucose

• Glycogen as a reservoir of glucose:
  • Liver and muscle store glycogen; liver glycogen serves to maintain blood glucose between meals, whereas muscle glycogen mainly supplies local energy during activity.
• Structure of glycogen:
  • Predominantly α-1,4 linkages with α-1,6 branch points creating a branched polysaccharide.
  • Primary link types described:
  • $\text{Glucose residues linked by } \alpha\text{-1,4 bonds}$
  • Branch points introduced by $\alpha\text{-1,6 bonds}$ at intervals to increase solubility and rapid mobilization.
• Synthesis of glycogen (in fed state, insulin-driven):
  • Glucose is first converted to glucose-1-phosphate (via phosphoglucomutase from G6P).
  • Then glucose-1-phosphate becomes UDP-glucose as above:
  • \text{Glucose-1-phosphate} + \text{UTP} \rightarrow \text{UDP-glucose} + \text{PP_i}
  • Glycogen synthase extends the glycogen chain by adding glucose units from UDP-glucose:
  • $\text{Glycogen}<em>{n} + \text{UDP-glucose} \rightarrow \text{Glycogen}</em>{n+1} + \text{UDP}$
  • Branching enzyme creates α-1,6 branches to optimize storage and mobilization.
• Glycogen breakdown (glycogenolysis) for rapid glucose:
  • Glycogen phosphorylase removes glucose-1-phosphate from non-reducing ends:
  • $\text{Glycogen}<em>{n} + \text{P</em>i} \rightarrow \text{Glycogen}_{n-1} + \text{Glucose-1-phosphate}$
  • In liver, glucose-6-phosphatase then converts G6P to glucose for release into blood:
  • $\text{Glucose-6-phosphate} \rightarrow \text{Glucose} + P_i$
  • In muscle, G6Pase is absent; G6P primarily enters glycolysis for local energy production.
• Insulin, GLUT4, and tissue-specific regulation:
  • Insulin triggers glycogen synthesis and glucose uptake in muscle and adipose tissue.
  • GLUT4 is the insulin-responsive glucose transporter translocating to the cell surface in muscle and adipose tissue to take up glucose.
  • In contrast, liver uses GLUT2 for glucose uptake and release, not GLUT4, aligning with its role in maintaining systemic glucose rather than rapid intracellular uptake for energy.
• Important nuance from the transcript (corrected context):
  • The discussion emphasizes liver as a key organ for releasing glucose via G6Pase and for storing glycogen; muscle acts as a glucose sink and local energy supplier via glycolysis.

Connections and broader implications

• Interplay between pathways during fed vs fasting states:
  • Fed state: insulin rises, promoting glucokinase activity in liver, glycogen synthesis, PPP (NADPH production), and fatty acid/steroid synthesis in tissues like liver and adipose.
  • Fasting state: glycogenolysis in liver releases glucose into blood; PPP activity may decrease; G6P is shunted into glycolysis or gluconeogenesis depending on demand; gluconeogenesis (via G6P to glucose) relies on G6Pase activity in liver and kidney.
• Stress, ATP shortage, and metabolic routing:
  • When ATP is scarce, cells increase pathways that regenerate ATP (glycolysis, glycogenolysis) and also generate NADPH for reductive reactions and detox processes.
• Hormonal and real-world relevance:
  • Insulin signaling drives glucose uptake in muscle/adipose (GLUT4) and stimulates lipid and glycogen synthesis.
  • Glucuronidation is a major detox pathway for bilirubin and drugs; defects can lead to jaundice and drug metabolism issues.
• Summary of the key enzymes mentioned:
  • Glucose-6-phosphatase (G6Pase): release of glucose from G6P in liver/kidney; absent in muscle.
  • Glucokinase (liver) vs Hexokinase (muscle): control points for glucose phosphorylation.
  • UDP-glucose pyrophosphorylase: forms UDP-glucose from glucose-1-phosphate + UTP.
  • UDP-glucose dehydrogenase: converts UDP-glucose to UDP-glucuronate (detox pathway).
  • Glycogen synthase and branching enzyme: glycogen assembly with α-1,4 linkages and α-1,6 branching.
  • Glycogen phosphorylase: glycogen breakdown to glucose-1-phosphate.
  • Glucose transporters: GLUT4 (insulin-responsive in muscle/adipose) vs GLUT2 (liver).

Quick reference: key reactions (LaTeX-formatted)

• Initial phosphorylation:
  • $\text{Glucose} + \text{ATP} \rightarrow \text{Glucose-6-phosphate} + \text{ADP}$
• Glucose-6-phosphatase step in liver/kidney:
  • $\text{Glucose-6-phosphate} \rightarrow \text{Glucose} + P_i$
• PPP oxidative phase (NADPH production):
  • $\text{G6P} + \mathrm{NADP^+} \rightarrow 6-\text{phosphoglucono-}\delta-\text{lactone} + \mathrm{NADPH}$
  • $6-\text{phosphogluconate} + \mathrm{NADP^+} \rightarrow \text{Ribulose-5-phosphate} + \mathrm{CO_2} + \mathrm{NADPH}$
• UDP-glucose formation:
  • \text{Glucose-1-phosphate} + \text{UTP} \rightarrow \text{UDP-glucose} + \text{PP_i}
• UDP-glucuronate formation (oxidation):
  • $\text{UDP-glucose} + 2\, \mathrm{NAD^+} + \mathrm{H_2O} \rightarrow \text{UDP-glucuronate} + 2\, \mathrm{NADH} + 2\, \mathrm{H^+}$
• Glycogen synthesis (glycogenin, synthase, branching):
  • \text{Glucose-1-phosphate} + \text{UTP} \rightarrow \text{UDP-glucose} + \text{PP_i}
  • $\text{Glycogen}<em>{n} + \text{UDP-glucose} \xrightarrow{\text{glycogen synthase}} \text{Glycogen}</em>{n+1} + \text{UDP}$
• Glycogen breakdown:
  • $\text{Glycogen}<em>n + \text{P</em>i} \rightarrow \text{Glycogen}_{n-1} + \text{Glucose-1-phosphate}$
• Glucose transporters (conceptual): GLUT4 translocation to plasma membrane in response to insulin in muscle/adipose; GLUT2 in liver for bidirectional glucose transport.